- Home
- TMCI vs NTHI Comparison
TMCI vs NTHI Comparison
Compare TMCI & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMCI | NTHI |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.6M | 195.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | TMCI | NTHI |
|---|---|---|
| Price | $2.59 | $6.73 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $6.87 | N/A |
| AVG Volume (30 Days) | ★ 777.8K | 71.7K |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $218,879,000.00 | $59,990.00 |
| Revenue This Year | $3.25 | N/A |
| Revenue Next Year | $1.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.90 | N/A |
| 52 Week Low | $2.44 | $3.20 |
| 52 Week High | $10.79 | $25.00 |
Technical Indicators
Market Signals| Indicator | TMCI | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 29.93 | 36.76 |
| Support Level | $2.64 | $8.63 |
| Resistance Level | $2.76 | $10.44 |
| Average True Range (ATR) | 0.20 | 0.93 |
| MACD | 0.09 | -0.19 |
| Stochastic Oscillator | 27.17 | 10.89 |
Price Performance
Historical ComparisonAbout TMCI Treace Medical Concepts Inc.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).